Research Projects

This database contains information on EU funded dementia research projects, undertaken since 2007. It is the product of a mapping exercise of European funding programmes for dementia research conducted by Alzheimer Europe in 2020. This database is not an exhaustive resource of information. It contains information about European projects that are funded by European programmes including FP7, H2020, IMI, JNPD, AAL and EU Health.

Filters

(Clear all)

Aetionomy – Organising Mechanistic Knowledge about Neurodegenerative Diseases for the Improvement of Drug Development and Therapy

AETIONOMY

IMI’s Call 8 is geared to develop knowledge frameworks for ‘druggable mechanisms’ for two domains of pathophysiology. In response to this call, we propose (I) the development of a generic AETIONOMY pipeline to capture and infer over mechanistic knowledge of pathophysiology, and  (II) the focused application of this pipeline to derive clinically...

Funding Programme
Start Date
End Date
Total Funding
€ 17 546 060

Alzheimer's disease apolipoprotein pathology for treatment elucidation and development

ADAPTED

Alzheimer’s disease (AD) affects over 35 million people worldwide and yet there are currently no medicines which slow down the progress of the disease. The ADAPTED project aims to boost the development of new medicines by investigating an area of AD research which has previously received little attention – the APOE gene. The APOE gene is a well...
Funding Programme
Start Date
End Date
Total Funding
€ 6 796 740
European Countries Involved

Amyloid imaging to Prevent Alzheimer’s Disease

AMYPAD

Beta-amyloid (β-amyloid) deposition is considered to be a necessary - but not sufficient - step on the path towards Alzheimer’s disease (AD). Depiction of brain β-amyloid in vivo can support an early diagnosis, and even provide an opportunity for consider secondary prevention of AD. Currently, however, the value of β-amyloid PET remains elusive...

Funding Programme
Start Date
End Date
Total Funding
€ 27 329 288

Efficiently networking European neurodegeneration research

NEURONET

IMI’s growing neurodegenerative disorders (ND) portfolio is to get a new, dynamic platform – NEURONET – that will make it easier for the many projects to exploit synergies and connect the resources and needs of the different projects. NEURONET aims to be a key enabler and mediator across the portfolio, assisting in identifying gaps, multiplying...
Funding Programme
Start Date
End Date
Total Funding
€ 2 353 125
European Countries Involved

European Bank for induced pluripotent Stem Cells

EBiSC

Induced pluripotent stem cells (iPSC) are the cornerstone of many regenerative medicine projects, and offer researchers a powerful new approach to model and study a range of diseases. The European Bank for Induced Pluripotent Stem Cells (EBiSC) was established to provide researchers across academia and the pharmaceutical industry with disease...
Funding Programme
Start Date
End Date
Total Funding
€ 34 327 858
European Countries Involved

European Medical Information Framework

EMIF

In response to the need to tackle increasingly complex medical research questions, a growing amount of human health data is being collected, either in routine Electronic Healthcare Record (EHR) databases, through research-driven cohort studies, in biobanks or related efforts. However, data sources are typically fragmented and contain information...
Funding Programme
Start Date
End Date
Total Funding
€ 53 642 677

European Prevention of Alzheimer’s Dementia Consortium

EPAD

The secondary prevention of Alzheimer’s dementia (AD) is achievable if we can identify individuals at risk of disease progression defined by biomarker evidence of AD pathology and no or only minimal clinical symptoms and engage them in a standing adaptive clinical trial, of the highest quality, testing multiple interventions.

To achieve this...

Funding Programme
Start Date
End Date
Total Funding
€ 53 237 842

European Quality In Preclinical Data

EQIPD

Pharmaceutical industry, as well as basic science, depend on robust data and scientific rigor as key drivers for decision making, patent strength and time-to-market, which in turn will determine knowledge gain and availability of new treatments to patients. Recent publications report challenges with the robustness, rigor, and/or validity of...

Funding Programme
Start Date
End Date
Total Funding
€ 9 845 484
European Countries Involved

Inflammation and AD: modulating microglia function focussing on TREM2 and CD33

PHAGO

Alzheimer’s disease (AD) is an age-related chronic neurodegenerative disease with four main pathological changes in the brain: amyloid plaques, fibrillary tau tangles, inflammation and neuronal loss. Phagocytes around amyloid plaques in late onset AD (LOAD) may be neurotoxic but have limited motility and phagocytic activity, suggesting a...

Funding Programme
Start Date
End Date
Total Funding
€ 18 088 176

Inhibiting Misfolded protein PRopagation in Neurodegenerative Diseases

IMPRiND

Assemblies of tau and α-synuclein were shown to spread along interconnected neuronal networks suggesting broadly relevant therapeutic directions for Alzheimer’s and Parkinson’s disease. This requires a pre-clinical stage of development that has yet to be met. The scale of neurodegenerative disease burden in Europe calls for an unprecedented...

Funding Programme
Start Date
End Date
Total Funding
€ 11 363 398
European Countries Involved

Investigating Mechanisms and Models Predictive of Accessibility of Therapeutics (IM2PACT) Into The Brain

IM2PACT

The overall aim is to further the understanding of the BBB in health and disease states towards the development of innovative brain delivery systems, especially for biopharmaceuticals (e.g., peptides, antibodies, etc.) and the identification of novel disease drug targets (Alzheimer’s Disease, MS, metabolic disease).

The related key deliverables...

Funding Programme
Start Date
End Date
Total Funding
€ 17 410 136

Models of patient engagement for Alzheimer’s disease

MOPEAD

Dementia researchers are increasingly focusing their efforts on finding ways to prevent the onset of dementia symptoms in the first place, and for this they need to work with people who are still in the very earliest stages of the disease. The MOPEAD project aims to identify and test different models for engaging with this important group and...

Funding Programme
Start Date
End Date
Total Funding
€ 4 591 968
European Countries Involved
 
Acknowledgement
Alzheimer Europe's database on research projects was developed as part of the 2020 Work Plan which received funding under an operating grant from the European Union’s Health Programme (2014–2020).